Retatrutide and Motivation: Energy and Mood

    By Trimi Medical Team11 min read

    The relationship between retatrutide and motivation is paradoxical. On one hand, significant weight loss (up to 24.2% per Jastreboff et al., NEJM 2023) often produces a surge of energy, confidence, and motivation that patients describe as life-changing. On the other, the caloric restriction and GI side effects of treatment can cause fatigue and low energy, especially during dose escalation. Understanding this dual nature helps patients set realistic expectations and optimize their experience.

    Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Persistent fatigue or mood changes should be evaluated by your healthcare provider.

    The Energy Timeline

    Weeks 1-4: Many patients experience fatigue as the body adjusts to caloric restriction and the medication's metabolic effects. GI side effects (nausea, appetite loss) reduce food intake, which can lower energy. This is the most challenging period.

    Months 2-4: As the body adapts and weight loss becomes noticeable, many patients report increasing energy. Improved sleep (especially if sleep apnea improves), reduced joint pain, and improved cardiovascular fitness all contribute.

    Months 4-12: The "sweet spot" for most patients. Significant weight loss has improved physical capacity, self-confidence is building, and the medication is well-tolerated. Many describe this as feeling better than they have in years or decades.

    How Weight Loss Improves Motivation

    • Physical energy: Carrying less weight means every physical activity requires less effort. Walking, climbing stairs, and exercise become easier and more enjoyable.
    • Sleep quality: Weight loss often improves sleep apnea, snoring, and overall sleep quality, leading to better daytime energy.
    • Reduced inflammation: Obesity causes chronic low-grade inflammation that contributes to fatigue. Weight loss reduces inflammatory markers.
    • Blood sugar stability: Improved glycemic control prevents energy crashes from blood sugar swings.
    • Confidence cascade: Visible results build confidence, which increases motivation for exercise and healthy eating, which produces more results, creating a positive cycle.
    • Social energy: Improved self-image often leads to greater social engagement and activity.

    Managing Low Energy Periods

    • Ensure adequate calories: Do not eat below 1,000-1,200 calories daily. Extreme restriction causes fatigue.
    • Prioritize protein: Protein provides sustained energy and prevents muscle loss that contributes to fatigue.
    • Stay hydrated: Dehydration from GI side effects is a common cause of fatigue.
    • Monitor B12 and iron: Both can become depleted with reduced food intake.
    • Light exercise: Counterintuitively, gentle exercise often improves energy. Even a 15-minute walk can boost mood and alertness.
    • Sleep hygiene: Prioritize 7-9 hours. Good sleep amplifies all other energy strategies.

    Mood Effects

    Most patients experience improved mood with weight loss, driven by better physical health, increased self-confidence, and improved social interactions. However, some patients experience mood changes during treatment that warrant attention: irritability during caloric restriction, anxiety about weight regain, frustration during plateaus, and rarely, depression. If mood changes are persistent or severe, discuss with your provider. They may be related to nutritional deficiencies, medication effects, or underlying mental health conditions that are unmasked by the weight loss process.

    Sustaining Long-Term Motivation

    • Set non-scale goals (fitness milestones, clothing sizes, activity achievements)
    • Track multiple metrics (measurements, photos, energy levels, lab values)
    • Build a support network (provider, friends, online communities)
    • Celebrate milestones without food-centered rewards
    • Develop an exercise routine you genuinely enjoy
    • Remember your "why" during challenging periods

    GLP-1 Treatment With Motivational Support

    Trimi provides compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with ongoing medical support that helps patients stay motivated throughout their journey. Learn how Trimi works.

    Frequently Asked Questions

    Will retatrutide make me tired?

    Initially, yes, some fatigue is common as your body adjusts to reduced caloric intake. However, most patients report significantly improved energy levels once weight loss becomes substantial (usually after 2-3 months).

    Does retatrutide affect mood directly?

    GLP-1 receptors are expressed in brain areas involved in mood regulation. Some research suggests GLP-1 medications may have direct mood-improving effects, though this is not yet definitively established for retatrutide.

    How do I stay motivated during a plateau?

    Focus on non-scale victories, review progress photos, remember how far you have come, and consider that plateaus are temporary and normal. Adjusting exercise and nutrition strategies can help break through.

    Can retatrutide help with depression?

    Weight loss and improved physical health often improve depressive symptoms, but retatrutide is not a treatment for clinical depression. Continue any existing mental health treatment and discuss mood changes with your provider.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: June 2, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook
    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Clinician-reviewed Trimi guide to GLP-1: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded GLP-1 option compares to brand alternatives.

    Clinician-reviewed Trimi guide to retatrutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded retatrutide option compares to brand alternatives.

    Clinician-reviewed Trimi guide to retatrutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded retatrutide option compares to brand alternatives.

    Clinician-reviewed Trimi guide to GLP-1: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded GLP-1 option compares to brand alternatives.

    Start your GLP-1 journey — from $99/mo

    Get Started